- Home
- OCS vs OABI Comparison
OCS vs OABI Comparison
Compare OCS & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OCS | OABI |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 732.4M | 696.4M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OCS | OABI |
|---|---|---|
| Price | $7.96 | $4.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | ★ $37.01 | $8.33 |
| AVG Volume (30 Days) | 316.3K | ★ 1.3M |
| Earning Date | 11-03-2026 | 10-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,666,000.00 |
| Revenue This Year | N/A | $87.73 |
| Revenue Next Year | $365.20 | $25.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.11 | $1.32 |
| 52 Week High | $34.48 | $5.43 |
Technical Indicators
Market Signals| Indicator | OCS | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 38.47 | 48.14 |
| Support Level | $7.11 | $4.51 |
| Resistance Level | $13.49 | $5.06 |
| Average True Range (ATR) | 0.45 | 0.30 |
| MACD | 0.15 | -0.04 |
| Stochastic Oscillator | 50.87 | 37.61 |
Price Performance
Historical ComparisonAbout OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
About OABI OmniAb Inc.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.